MoonLake Immunotherapeutics reports results for the quarter ended September 30 - Earnings Summary

What happened

MoonLake Immunotherapeutics reported an adjusted loss of 93 cents per share for the quarter ended September 30, compared with a loss of $-1.10 per share in the same quarter last year. Revenue was zero, matching analysts’ expectations, while the reported loss was wider than the average forecast.

Confirmed

Global impact / market context

The loss exceeding analysts’ average forecast may sharpen attention on how MoonLake funds its operations while reporting no revenue. For investors, the gap between results and expectations can influence views of execution, while the absence of sales leaves future revenue development central to the investment case.

Analyst inference

Analysts’ average earnings estimate had risen about 14.7% over three months, with no revisions in the past 30 days, even as the reported loss exceeded the average forecast. The shares were unchanged so far this quarter but down 11.2% year to date.

Confirmed

What to watch

1. Watch upcoming quarterly reports for any revenue and for changes in losses; revenue growth would show whether the company is beginning to generate sales. Analyst inference
2. Analysts’ average rating was buy, with 12 buy or strong-buy, two hold, and two sell or strong-sell recommendations; subsequent rating changes could shift investor expectations. Confirmed
3. The median 12-month analyst price target was $30, about 61% above the last closing price of $11.70; compare later target updates with results and forecasts. Confirmed

Evidence

• Original source link unavailable